MMP-26的同源模建及S_1'结合袋的结构特点

以基质金属蛋白酶-12(MMP-12)的晶体结构为模板,采用同源模建方法构建了基质金属蛋白酶-26(MMP-26)的三维结构,并阐明了其S1'结合袋的结构特点,MMP-26中His233残基插入S1'结合袋,限制了S1'结合袋的深度,符合中袋MMPs的特点,因此MMP-26属于中袋MMPs.在此基础上,研究了抑制剂GM6001与MMP-26的相互作用模式,发现GM6001中异羟肟酸结构的羰基氧和羟基氧与催化锌离子发生双齿配位,符合异羟肟酸类MMPs抑制剂的配位特点.     

基质金属蛋白酶与天然黄酮醇类药物抑制剂识别机理的光谱学研究

基质金属蛋白酶(Matrix metalloproteiriases, MMPs)是肿瘤细胞对正常组织的侵袭和转移过程中重要的调节因子, 可以水解多种细胞内、细胞外及细胞膜上的底物, 因而影响着多种细胞的行为.当MMPs表达异常时, 很多种病理会改变甚至恶化, 因此, MMPs已成为近年来备受关注的一类抗肿瘤药物靶标蛋白酶. 选用MMPs的几种天然黄酮醇类药物小分子抑制剂,利用荧光滴定光谱和紫外-可见(UV-Vis)吸收光谱相结合, 研究了它们与MMPs家族成员之一MMP-16之间的分子识别和作用机理. 研究结果表明, 这几种黄酮醇化合物不但对MMP-16显示出了较强的结合能力, 而且在结合模式、结合比和抗氧化性能等多方面都表现出了很强的结构-性能差异.     

流动注射化学发光法测定水中焦性没食子酸

在0.05 m01·L-1氢氧化钠溶液中,高碘酸钾与鲁米诺产生化学发光,焦性没食子酸对该发光有显著的增强作用.基于此,并结合流动注射技术,提出了在水样中测定焦性没食子酸的方法.在选定的条件下,化学发光信号的增加值与焦性没食子酸质量浓度之间在1.0～,100 μg·L-1及0.1～2.0 mg·L-1叫之间呈线性关系,该方法的检出限为0.78μg·L-1(30);对10μg·L-1焦性没食子酸平行测定11次,其相对标准偏差为3.9%.该方法已应用于工业废水和环境水样中焦性没食子酸的测定,并用标准加入法作了回收试验,测得回收率在95.7%～104.1%之间.     

Hydroxamate类抑制剂与MMP-3的结合自由能的计算

用自由能微扰方法(FEP)计算了两种hydroxamate类的抑制剂和MMP-3的相对结合自由能。在计算中,对于催化区的锌离子与其共价结合的配体(包括抑制和组氨酸)采用了键合的模型,抑制剂和周围配体的部分电荷的计算采用两步静电势收敛方法。自由能计算采用了慢增长(Slowgrowth)和固定窗口增长(Fixedwidthwindowgrowth)两种方法,并且在每次计算中都采用了双向采样(Double-widesampling)的策略。两种方法计算得到的相对结合自由能都能和实验值很好的符合。同时从动力学模拟的得到的分子轨迹得到了抑制剂和受体之间相互作用模式,抑制剂的P1部分可以和受体的S1'口袋形成很强范德华和疏水相互作用,P1上的苯环可以和Tyr223上的苯环形成较好的π键堆积相互作用。     

杨梅酮的抗氧化活性

采用密度泛函理论(DFT)方法, 研究了杨梅酮的分子结构、电子结构和羟基离解焓, 并探讨了杨梅酮与OOCH₃·自由基发生反应的抗氧化机理. 自由基发生反应的抗氧化机理. 在M06-2X/6-31++G(d,p)的计算水平下, 得到了杨梅酮脱氢后各种自由基的相对能量、羟基离解焓、氢原子提取的活化能垒和速率常数. 计算结果表明杨梅酮的4'-OH位置具有最高的抗氧化活性. 杨梅酮4'-OH位置的高活性, 主要是由于4'位上脱氢后生成的羰基与相邻的羟基之间形成了稳定的氢键. 分子中的原子(AIM)理论分析表明, 这种氢键相互作用能够稳定氢提取过程中产生的自由基. 对杨梅酮抗氧化性机理的理论研究, 可为今后设计合成新型的具有更强活性的抗氧化物提供坚实的理论基础.     

基于配体与受体结构的酪氨酸酶抑制剂定量构效关系分析

酪氨酸酶是细胞内催化合成黑素的关键酶。 理解酪氨酸酶抑制剂结构与活性之间的关系对于设计新药和化妆品具有重要意义。 然而,酪氨酸酶抑制剂的定量构效关系仍不清楚。 本文利用配体和结构描述符构建了隐式和显式模型,阐明了酪氨酸酶抑制剂定量构效关系。 隐式模型的相关系数R高达0.961,显式模型的相关系数为0.775。 两个模型很好地预测了3个茶多酚的酪氨酸酶抑制活性,表儿茶素没食子酸酯(ECG)>表没食子儿茶素没食子酸酯(EGCG)>没食子酸(G)。 相关性分析发现,抑制剂与酪氨酸酶结合引起的构象熵损失与抑制剂的活性密切相关。 具有较少构象熵损失的ECG在4种茶多酚中具有较高酪氨酸酶抑制活性。 结合自由能计算也证实ECG与酪氨酸酶的结合能力最强。 此外,通过分解结合自由能发现,酪氨酸酶活性中心的氨基酸残基(His57、His201、Asn202、His205、Glu192和Val215)与抑制剂形成了较强的范德华和静电相互作用,进而稳定了复合物结构。     

α-卤代丁二酰氧肟酸类基质金属蛋白酶抑制剂的合成及活性评价

基质金属蛋白酶(MMPs)是一族Zn2+依赖的蛋白水解酶. 该族酶的过度表达与多种病理过程密切相关, 因此其抑制剂可用于这些疾病的治疗. 本文设计合成了15个α-卤代丁二酰氧肟酸类新型基质金属蛋白酶抑制剂, 经核磁共振氢谱和质谱进行了结构表征, 并以伊洛马司他(Ilomastat)为阳性对照, 分别测定了它们对基质金属蛋白酶MMP-2和MMP-9的体外抑制活性. 结果显示, 4个化合物对MMP-2的抑制活性与阳性对照相当; 5个化合物对MMP-9的抑制活性与对照药相当.     

硝基二肽类嗜热菌蛋白酶抑制剂的分子动力学研究

采用分子对接和分子动力学方法,考察了硝基类二肽类化合物抑制剂的侧链结构对嗜热菌蛋白酶(TLN)的抑制效能的影响.计算结果表明:当侧链基团为异丁基时,抑制剂与TLN的活性部位之间形成的氢键数目最多,并可以提高抑制剂与TLN的结合能力.理论计算的结合自由能大小与抑制剂的抑制常数相吻合.以上结果从理论上进一步揭示了硝基类二肽化合物侧链结构对TLN的抑制能力的影响复杂性,即除了一般意义上的疏水作用外,侧链结构的变化导致氢键的形成能力变化也不可忽略.     

乙酰胆碱酯酶AChE与1,7-二氮杂咔唑抑制剂的作用机理的分子动力学模拟

通过分子对接、分子动力学(MD)模拟以及成键自由能分析方法,从原子水平上模拟研究了3种1,7-二氮杂咔唑衍生物(分别记为M1、M2和M3)与ACh E的结合模式及相互作用机理,分析和讨论了研究体系的静电相互作用和范德华相互作用(vd W)。用MM-PBSA方法计算的3种抑制剂与ACh E之间的结合自由能与抑制剂的实验生物活性数据(IC50值)相对应。分析结果表明,残基S286与抑制剂之间形成的氢键作用有利于抑制剂与ACh E之间的结合。范德华相互作用,尤其是抑制剂与关键残基W279和Y334的作用,对抑制剂与ACh E之间的结合自由能有较大的贡献,在区分抑制剂M1(或M2)和M3的生物活性上发挥着重要的作用。     

荧光及ESI质谱法研究溶菌酶与磷酰化黄酮的相互作用

分别用荧光法和ESI质谱法研究了磷酰化黄酮和溶菌酶的相互作用 .结果均显示磷酰化黄酮能够和溶菌酶发生弱相互作用 ,与黄酮相比它对溶菌酶更具亲和力 .根据荧光猝灭双倒数图计算了磷酰化黄酮与溶菌酶之间的结合常数为k2 0℃ =1.68× 10 4L/mol,k3 7℃ =1.0 6× 10 4L/mol,实验证明随着温度的升高 ,磷酰化黄酮与溶菌酶的结合常数逐渐降低 ,说明了两者之间形成了复合物 ,此荧光猝灭过程为静态猝灭 .根据F ster能量传递原理计算出磷酰化黄酮在溶菌酶上的结合距离 ,并根据热力学参数确定了磷酰化黄酮与溶菌酶之间的作用力类型为电荷作用力     

Structural basis for the highly selective inhibition of MMP-13

Inhibitors for matrix metalloproteinases (MMPs) are under investigation for the treatment of cancer, arthritis, and cardiovascular disease. Here, we report a class of highly selective MMP-13 inhibitors (pyrimidine dicarboxamides) that exhibit no detectable activity against other MMPs. The high-resolution X-ray structures of three molecules of this series bound to MMP-13 reveal a novel binding mode characterized by the absence of interactions between the inhibitors and the catalytic zinc. The inhibitors bind in the S1' pocket and extend into an additional S1' side pocket, which is unique to MMP-13. We analyze the determinants for selectivity and describe the rational design of improved compounds with low nanomolar affinity.     

Computational insights into the selectivity mechanism of APP-IP over matrix metalloproteinases

In this work, selectivity mechanism of APP-IP inhibitor (β-amyloid precursor protein-derived inhibitory peptide) over matrix metalloproteinases (MMPs including MMP-2, MMP-7, MMP-9 and MMP-14) was investigated by molecular modeling methods. Among MMPs, MMP-2 is the most favorable one for APP-IP interacting based on our calculations. The predicted binding affinities can give a good explanation of the activity difference of inhibitor APP-IP. In Comparison with MMP-2/APP-IP complex, the side chain of Tyr214^MMP-7 makes the binding pocket so shallow that the whole side chain of Tyr3^APP-IP can not be fully embraced, thus unfavorable for the N-terminal of APP-IP binding to MMP-7. The poor selectivity of APP-IP toward MMP-9 is mainly related with the decrease of interaction between the APP-IP C-terminal and MMP-9 due to the bulky side chains of Pro193 and Gln199, which is in agreement with experiment. The mutations at residues P193A and Q199G of MMP-9 alternate the binding pattern of the C-terminal of APP-IP by forming two new hydrogen bonds and hydrophobic interactions with MMP-9. The mutants favor the binding affinity of MMP-9 largely. For MMP-14/APP-IP, the large steric effect of Phe204^MMP-14 and the weak contributions of the polar residues Asn231^MMP-14 and Thr190^MMP-14 could explain why MMP-14 is non-selective for APP-IP interacting. Here, the molecular modeling methods were successfully employed to explore the selective inhibitor of MMPs, and our work gives valuable information for future rational design of selective peptide inhibitors toward individual MMP.     

Carbohydrate-lipid interactions: affinities of methylmannose polysaccharides for lipids in aqueous solution

The interactions between 3-O-methyl-mannose polysaccharides (MMPs), extracted from Mycobacterium smegmatis (consisting of a mixture of MMP-10, -11, -12 and -13) or obtained by chemical synthesis (MMP-5(s) , -8(s) , -11(s) and -14(s) ), and linear saturated and unsaturated fatty acids (FAs), and a commercial mixture of naphthenic acids (NAs) in aqueous solution at 25?°C and pH?8.5 were quantified by electrospray ionization mass spectrometry (ESI-MS). Association constants (K(a) ) for MMP binding to four FAs (myristic acid, palmitic acid, stearic acid and trans-parinaric acid) were measured by using an indirect ESI-MS assay, the "proxy protein" method. The K(a) values are in the 10(4) -10(5) M(-1) range and, based on results obtained for the binding of the synthetic MMPs with palmitic acid, increase with the size of the carbohydrate. Notably, the measured affinity of the extracted MMPs for trans-parinaric acid is two orders of magnitude smaller than the reported value, which was determined by using a fluorescence assay. Using a newly developed competitive binding assay, referred to as the "proxy protein/proxy ligand" ESI-MS method, it was shown that MMPs bind specifically to NAs in aqueous solution, with apparent affinities of approximately (5×10(4) )?M(-1) for the mixture of NAs tested. This represents the first demonstration that MMPs can bind to hydrophobic species more complex than those containing linear alkyl/alkenyl chains. Moreover, the approach developed here represents a novel method for probing carbohydrate-lipid interactions.     

New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups

In an effort to identify promising non-hydroxamate inhibitors of matrix metalloproteinases (MMPs), several new zinc-binding groups (ZBGs) based on pyrone, pyrothione, hydroxypyridinone, and hydroxypyridinethione chelators have been examined. Structural studies with tris(pyrazolyl)borate model complexes show that these ligands bind to the MMP active site zinc(II) ion in a bidentate fashion, similar to that found with hydroxamate-based inhibitors. Fluorescence- and colorimetric-based enzyme assays have been used to determine the IC50 values for these ZBGs against MMP-3; mixed O,S-donor ligands were found to be remarkably potent, with IC50 values as much as 700-fold lower than that found for acetohydroxamic acid. Inhibitory activity was found to parallel metal binding affinity as determined in titrations with model complexes. These results demonstrate that MPIs based on new ZBGs are feasible and may indeed improve the overall performance of inhibitors designed against these important medicinal targets.     

Design and characterization of a metalloproteinase inhibitor-tethered resin for the detection of active MMPs in biological samples

Matrix metalloproteinases (MMPs), zinc-dependent endopeptidases, are implicated in tumor progression. We describe herein the development of a resin-immobilized, broad-spectrum synthetic MMP inhibitor for selective binding of the active forms of MMPs from different experimental samples. We confirmed the activity-based binding of MMPs to the inhibitor-tethered resin with purified human recombinant MMP-2, -9, and -14, samples of cultured cells, and tissue extracts. Our results show that only the free active MMPs, and not the zymogens or MMP/TIMP (enzyme-protein inhibitor) complexes, bound specifically to the resin. In our comparison of benign and carcinoma tissue extracts, we detected active MMP-2 and MMP-14 forms only in the cancerous tissue samples, indicating that a pool of the tumor MMPs is free of endogenous inhibitors (TIMPs), and is thus likely to contribute to proteolytic events that precipitate tumor metastasis.     

Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management

Keratoconus (KC) is a serious disease that can affect people of any race or nationality, although the exact etiology and pathogenic mechanism are still unknown. In this study, thirty-two FDA-approved ophthalmic drugs were exposed to virtual screening using docking studies against both the MMP-2 and MMP-9 proteins to find the most promising inhibitors as a proposed computational mechanism to treat keratoconus. Matrix metalloproteinases (MMPs) are zinc-dependent proteases, and MMP inhibitors (MMPIs) are usually designed to interact with zinc ion in the catalytic (CAT) domain, thus interfering with enzymatic activity. In our research work, the FDA-approved ophthalmic medications will be investigated as MMPIs, to explore if they can be repurposed for KC treatment. The obtained findings of the docking study suggest that atenolol and ampicillin are able to accommodate into the active sites of MMP-2 and MMP-9. Additionally, both exhibited binding modes similar to inhibitors used as references, with an ability to bind to the zinc of the CAT. Molecular dynamic simulations and the MM-GBSA binding free-energy calculations revealed their stable binding over the course of 50 ns. An additional pharmacophoric study was carried out on MMP-9 (PDB ID: 1GKC) using the co-crystallized ligand as a reference for the future design and screening of the MMP-9 inhibitors. These promising results open the door to further biological research to confirm such theoretical results.     

Interactions between procyanidin oligomers and the active form of matrix metalloproteinase-7: A theoretical insight

The objective of this study was to determine the sites and modes of interaction of the most common oligomers of B-type procyanidins (PCs) with the active form of the matrix metalloproteinase-7 (MMP-7) and some molecular properties of the PCs by using theoretical methods. These data may provide useful insights into the ability of PCs to act as selective MMP-7 inhibitors. Some stereoisomers that predominated in the analyzed PCs (PB2, PC1, tetramer) could act as selective inhibitors of MMP-7 due to their interaction with amino acids of the subsites S2 and/or S1′ in the active site, and with some specific amino acids of MMP-7 that bind to cholesterol sulfate to promote proteolysis of the cell membrane. Hydrogen bonding was the main interaction of PB2 and PC1 with MMP-7, while in the tetramer, the van der Waals interactions prevailed. The determination of molecular properties such as chemical reactivity and stability by the highest occupied molecular orbital and lowest unoccupied molecular orbital gap, revealed that oligomers of PCs acquired very stable poses in their docking with MMP-7. Polarizability seems to be an important factor for PCs with large molecular volume (PC1, tetramer) to establish contact with amino acids of narrow subsites in the active site (S2, S1′) and amino acids located outside the active site.     

Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo[4,3-a]pyrimidinone Acyclo C-Nucleosides Multitarget Agents

The role of metalloenzymes in tumor progression had broadened their application in cancer therapy. Of these, MMPs and CAs are validated druggable targets that share some pivotal signaling pathways. The majority of MMPs or CAs inhibitors are designed as single-target agents. Despite their transient efficacy, these agents are often susceptible to resistance. This set the stage to introduce dual inhibitors of correlated MMPs and CAs. The next step is expected to target the common vital signaling nodes as well. In this regard, VEGFR-2 is central to various tumorigenesis events involving both families, especially MMP-2 and CA II. Herein, we report simultaneous inhibition of MMP-2, CA II, and VEGFR-2 via rationally designed hybrid 1,2,4-triazolo[4,3-a]pyrimidinone acyclo C-nucleosides. The promising derivatives were nanomolar inhibitors of VEGFR-2 (8; IC₅₀ = 5.89 nM, 9; IC₅₀ = 10.52 nM) and MMP-2 (8; IC₅₀ = 17.44 nM, 9; IC₅₀ = 30.93 nM) and submicromolar inhibitors of CA II (8; IC₅₀ = 0.21 µM, 9; IC₅₀ = 0.36 µM). Docking studies predicted their binding modes into the enzyme active sites and the structural determinants of activity regarding substitution and regioselectivity. MTT assay demonstrated that both compounds were 12 folds safer than doxorubicin with superior anticancer activities against three human cancers recording single-digit nanomolar IC₅₀, thus echoing their enzymatic activities. Up to our knowledge, this study introduces the first in class triazolopyrimidinone acyclo C-nucleosides VEGFR-2/MMP-2/CA II inhibitors that deserve further investigation.     

Activity-based enrichment of matrix metalloproteinases using reversible inhibitors as affinity ligands

Matrix metalloproteinases (MMPs) are zinc dependent metalloproteases characterized by the ability to cleave extracellular matrix and many other extracellular proteins. MMP activity is tightly regulated but disturbances in this regulation can contribute to various disease processes characterized by a progressive destruction of the extracellular matrix. The ability to profile classes of enzymes based on functionally related activities would greatly facilitate research about the involvement of MMPs in physiological and/or pathological states. Here we describe the characterization of an affinity sorbent using an immobilized reversible inhibitor as a stationary phase for the activity-based enrichment of MMPs from biological samples. With a ligand density of 9.8 mM and binding constant of 58 micromol/l towards MMP-12, the capturing power of the affinity sorbent was strong enough to extract MMP-12 spiked into serum with high selectivity from relatively large sample volumes. Experiments with endogenous inhibitors revealed that MMP-12 extraction is strictly activity-dependent, offering powerful means to monitor MMP activities in relation to physiological and/or pathological events by using affinity extraction as a first step in an MMP profiling method.